Please visit answersincme.com/BTD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses available and emerging frontline dual immunotherapy plus chemotherapy combination regimens for the treatment of patients with advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be able to: Review the role of PD-L1 expression in the selection of frontline immunotherapeutic regimens for patients with advanced NSCLC, with a focus on available and emerging frontline dual immunotherapy and chemotherapy combination regimens; Describe the clinical profiles of available and emerging frontline dual immunotherapy plus chemotherapy combination regimens for the treatment of patients with advanced NSCLC; and Outline strategies to integrate available and emerging dual immunotherapy and chemotherapy combination regimens into frontline settings through optimal patient selection and management.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related